The Epigenetics Discovery Congress
News May 21, 2015
As you may have heard epigenetic research is leading to many breakthrough discoveries in the field of therapeutics and diagnostics for many chronic diseases. But being a relatively new science there are very few success stories in the field most of them being in the research phase.
These case studies and more will be discussed at the Epigenetics Discovery Congress to be held in London - UK on 24 - 25 September 2015. The congress is bringing together leading industry and academic speakers who will be sharing their experiences on how they have been able to harness epigenetic research in drug discovery and diagnostic applications.
Some of the experts speaking at the conference are:
Dr. Rab Prinjha, VP Head of Epigenetics DPU, GSK
Dr. Tamara Maes, CSO, Oryzon
Dr. Paola Grandi, Group Leader, Cellzome
Dr. Peter Staller, Director of Oncology Research,EpiTherapeutics ApS
Dr. Remi Terranova, Senior Scientist, Novartis
Dr. Rajesh Chopra, MD, Corporate VP, Translational & Early Drug Development, Celgene
Get a chance to meet these experts and get a holistic overview of the updates on epigenetic research. Register today and get a early bird discount of 15% on registration fees; offer expires 31st May 2015.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.